Immuron (FRA:ANWA) Marketable Securities : €0.74 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Immuron Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Immuron's Marketable Securities for the quarter that ended in Dec. 2023 was €0.74 Mil.

Immuron's annual Marketable Securities stayed the same from Jun. 2021 (€0.00 Mil) to Jun. 2022 (€0.00 Mil) but then increased from Jun. 2022 (€0.00 Mil) to Jun. 2023 (€1.14 Mil).

Immuron Marketable Securities Historical Data

The historical data trend for Immuron's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Marketable Securities Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Marketable Securities

Get a 7-Day Free Trial

1.14

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Marketable Securities	Get a 7-Day Free Trial												-	-	0.43	1.14	0.74

Immuron Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Immuron (FRA:ANWA) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Immuron Marketable Securities Related Terms

Thank you for viewing the detailed overview of Immuron's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (FRA:ANWA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANWA) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

IMRN:USA IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANWA) Headlines

No Headlines